A carregar...

Memantine and cholinesterase inhibitor combination therapy for Alzheimer's disease: a systematic review

BACKGROUND: Memantine is licensed for moderate-to-severe Alzheimer's disease (AD). National Institute for Clinical Excellence (NICE) guidance does not recommend the use of memantine in combination with cholinesterase inhibitors (acetylcholinesterase inhibitor (AChEI)). The underpinning meta-ana...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Farrimond, Lucy E, Roberts, Emmert, McShane, Rupert
Formato: Artigo
Idioma:Inglês
Publicado em: BMJ Group 2012
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3378937/
https://ncbi.nlm.nih.gov/pubmed/22689908
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bmjopen-2012-000917
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!